The Harrington Discovery Institute: Developing Promising Discoveries
By: Erin Reese
The Harrington Discovery Institute (HDI) – part of The Harrington Project for Discovery & Development – is an international initiative with programs designed to enable inventive scientists to advance their discoveries into medicines that will improve human health.
Through annual competitions, HDI selects scientists whose projects are grant-funded to support advancement of their discoveries. These competitions include both general and disease-specific opportunities, all with the goal of ensuring that promising discoveries are given a chance to cross the biotech valley of death, moving from bench to bedside to the patients who need them most.
In addition to grant funding, competition winners also gain access to the Innovation Support Center (ISC), a group of experienced industry professionals who provide guidance to advance discoveries toward commercialization. The ISC provides valuable assistance including mentorship, resource connections, and business guidance to assist scientists in advancing their discoveries.
HDI’s annual competitions include:
Harrington Scholar-Innovator Award: This award is open to research in any disease, providing a guaranteed initial grant funding, and the opportunity to qualify for additional funding over the course of two years.
ADDF-Harrington Scholar Award: Co-sponsored with the Alzheimer’s Drug Discovery Foundation, this award is focused on finding new treatments for Alzheimer’s Disease.
Gund-Harrington Scholar Award: Co-sponsored with the Foundation Fighting Blindness, this award is focused on finding new treatments for retinal degenerative diseases.
The Harrington Rare Disease Scholar Award: Co-sponsored with Takeda, this program was created to advance breakthrough research into novel treatments for rare diseases.
The Oxford-Harrington Scholarship Programme: In partnership with the University of Oxford, this award provides support to researchers working on novel drug discovery research problems that have demonstrable potential to become new therapies, but may not be far enough along the drug development path to attract committed financial investors